Central Texas Veterans' Healthcare System

Olin E. Teague Veterans’ Medical Center

         

Initial Study Results from Ongoing EOScu Clinical Trial at the

Olin E. Teague Veterans’ Medical Center


%

Mean bioburden on copper surface was 81% lower at hour 30 than non-copper

Copper-impregnated tray tables had lower microbial burden than standard material

Bioburden difference between surfaces was statistically significant beyond 24 hours


 


Evaluating the Clinical Benefits of EOScu

In June 2016, EOS Surfaces officially entered into a CRADA (Cooperative Research and Development Agreement) with the Central Texas Veterans Health Care System in Temple, TX. A CRADA is a legal “contract” that allows the Department of Veterans Affairs (VA) to enter into a relationship with a private company in the interest of studying the potential impact of technologies on the care of veterans while not violating the rules that prohibit financial investments or formal endorsements. The study will further test the efficacy of EOS Surfaces’ copper-infused hard surface, EOScu,  in reducing both the bioburden as well as its impact on the hospital acquired infection (HAI) rates in a healthcare setting.

Microscope Trial

The Trial

The facility will outfit all 120 patient rooms with EOScu Preventive|Biocidal Surfaces™ (Cupron Enhanced EOS). The Olin E. Teague VAMC installation will include all countertops, over-the-bed tables and bed rails in the facility, providing additional protection against bacterial infection above and beyond existing infection control protocols.

Recent studies demonstrate that surfaces play a large role in the transmission of disease-causing pathogens by serving as reservoirs. Bioburden, the amount of microbiological or organic material on an object prior to decontamination or sterilization, has been demonstrated to correlate with infection rates. The earliest phase of the study aims to confirm how EOScu decreases the bacteria on the surface between routine sanitation efforts. The trial will also include a longer term study to verify EOScu‘s to reduce HAIs and costs associated with readmissions.

The Location

The trial was launched in October 2016 at the Olin E. Teague Veterans’ Medical Center (VAMC), part of the Central Texas Veterans’ Healthcare System, located in Temple, Texas.

As one of the largest healthcare systems in the US, the Veterans Health Administration (VHA) provides essential care to more than 8.7 million veterans in 300 VA hospitals, as well as 827 community-based outpatient clinics. Veterans are particularly vulnerable to HAIs and as a result, VA has made infection prevention a top priority. Its Health Services Research & Development Service (HSR&D) has conducted several studies focused on detecting and preventing HAIs.

Microscope Trial

The company’s second, large-scale trial includes:

  • EOScu Preventive|Biocidal SurfacesTM installed on most horizontal surfaces in the 120 patient rooms as well as common areas such as nurses’ stations.
  • Each patient room will also have EOScu overbed tables, bed rail kits, side tables, and sinks/vanities.
  • Multiple publications, including short-term bioburden research and longer-term research on the impact of EOScu Preventive|Biocidal SurfacesTM on HAI rates
Microscope Trial

While routine sanitation procedures are essential, bacteria can repopulate and reproduce in a room right after rigorous cleanings, and we searched for a solution that would fill the gaps and build upon our current initiatives. We predict that the test will provide real-world data confirming the surface’s ability to constantly reduce bacterial contamination and HAI-associated costs, which will bolster our efforts to protect our Veterans, staff and community.

– Principal Investigator, Olin E. Teague’s VA Medical Center, Temple, TX

Central Texas Veterans Health Care System

See the EOScu difference

Request a sample today